Immunocytochemical detection of endoglin is indicative of angiogenesis in malignant melanoma

Anticancer Research

Volumn 18, Issue 4 A, 1998, Pages 2701-2710

  Bodey, Bela ^a,d   Bodey Jr , Bela ^a   Siegel, Stuart E ^b   Kaiser, Hans E ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b CHILDREN S HOSPITAL LOS ANGELES   (United States)

^c UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^d NONE   (United States)

Author keywords

Antiangiogenic therapy; Carcinogenesis; Cellular immunophenotype (CIP); Endoglin (CD105 EDG); Endothelial cell markers; Malignant melanoma (MM); Neoplasm related angiogenesis (NRA); Vascular endothelial growth factor permeability factor (VEGF PF)

Indexed keywords

ALKALINE PHOSPHATASE; BIOTIN; DIAMINOBENZIDINE; ENDOGLIN; STREPTAVIDIN;

ANGIOGENESIS; ANTIGEN DETECTION; ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; MELANOMA; PRIORITY JOURNAL; TISSUE SECTION;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD; CAPILLARIES; CELL TRANSFORMATION, NEOPLASTIC; DIMERIZATION; HUMANS; IMMUNOHISTOCHEMISTRY; MELANOMA; NEOVASCULARIZATION, PATHOLOGIC; RECEPTORS, CELL SURFACE; TRANSFORMING GROWTH FACTOR BETA; TUMOR MARKERS, BIOLOGICAL; VASCULAR CELL ADHESION MOLECULE-1;

EID: 0031863820     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (202)

1. Kaiser HE: Progression of neoplasms deriving from pigmented tissues. In: Cancer Growth and Progression, Gorelik EL (ed) Dordrecht: Kluwer Academic Publishers, 1989, Vol 8, Ch 16, pp175-218.
2. Legha SS: Current therapy for malignant melanoma. Sem Oncol 16: 34-44, 1989.
3. Fountain JW, Bale SJ, Housman DE, Dracopoli NC: Genetics of Melanoma. Cancer Surveys 9: 645-671, 1990.
4. Clark WH, Jr, Elder DE, Guerry D, Epstein ME, Greene MH, van Horn M: A study of tumor progression: the precursor lesions of superficial spreading and nodular melanoma. Human Pathol 15: 1147-1165, 1984.
5. Poste G: Pathogenesis of metastatic disease: Implications for current therapy and for the development of new therapeutic strategies. Cancer Treat Rep 70: 183-198, 1986.
6. Duray PH, Palazzo J, Gown AM, Ohuchi N: Melanoma Cell Heterogeneity. Cancer 61: 2460-2468, 1988.
7. Guerry D, Synnestvedt M, Elder DE, Schultz D: Lessons from tumor progression. The invasive radial growth phase of melanoma is common, incapable of metastasis, and indolent. J Invest Dermatol 100: S342-S345, 1993.
8. Herlyn M, Clark WH, Rodeck U, Mancianti ML, Jambrosic J, Koprowski H: Biology of tumor progression in human melanocytes. Lab Invest 56: 461-474, 1987.
9. Fearon ER, Vogelstein B: A genetic model for colorectal carcinogenesis. Cell 61: 759-767, 1990.
10. Kerbel RS: Expression of multi-cytokine resistance and multigrowth factor independence in advanced stage metastatic cancer. Malignant melanoma as a paradigm. Am J Pathol 141: 519-524, 1992.
11. Lu C, Kerbel RS: Interleukin-6 undergoes transition from paracrine growth inhibitor to autocrine stimulator during human melanoma progression. J Cell Biol 120: 1281-1288, 1993.
12. Weterman MAJ, van Muijen GNP, Bloemers HPJ, Ruiter DJ: Biology of Disease. Molecular markers of melanocytic tumor progression. Lab Invest 70: 593-608, 1994.
13. Gastl G, Hermann T, Steurer M, Zmija J, Gunsilius E, Unger C, Kraft A: Angiogenesis as a target for tumor treatment. Oncology 54: 177-184, 1997.
14. Folkman J: Angiogenesis in cancer, vascular, rheumatoid, and other disease. Nature Med 1: 27-31, 1995.
15. Cockerill GW, Gamble JR, Vadas MA: Angiogenesis: models and modulators. Int Rev Cytol 159: 113-160, 1995.
16. Risau W: Differentiation of endothelium. FASEB J 9: 926-933, 1995.
17. Risau W, Flamme I: Vasculogenesis. Annu Rev Cell Dev Biol 11: 73-91, 1995.
18. Hanahan D, Folkman J: Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86: 353-364, 1996.
19. Bicknell R, Harris AL: Mechanisms and therapeutic implications of angiogenesis. Curr Opin Oncol 8: 60-65, 1996.
20. Folkman J: Addressing tumor blood vessels. Nature Biotechnol 15: 510, 1997.
21. Folkman J: Angiogenesis and angiogenesis inhibition: an overview. EXS 79: 1-8, 1997.
22. Pietsch T, Valter MM, Wolf HK, von Deimling A, Su Huang H-J, Cavenee WK, Wiestler OD: Expression and distribution of vascular endothelial growth factor protein in human brain tumors. Acta Neuropathol 93: 109-117, 1997.
23. Price JT, Bonovich MT, Kohn EC: The biochemistry of cancer dissemination. Crit Rev Biochem Mol Biol 32: 175-253, 1997.
24. Salven P, Heikkila MD, Anttonen A, Kajanti M, Joensuu H: Vascular endothelial growth factor in squamous cell head and neck carcinoma: expression and prognostic significance. Modern Pathol 10: 1128-1133, 1997.
25. Folkman J, Klagsbrun M: Angiogenic factors. Science 235: 442-447, 1987.
26. Keck PJ, Hauser SD, Krivi G, Saazo K, Warren T, Feder J, Connolly DT: Vascular permeability factor, an endothelial cell mitogen related to PDGF. Science 246: 1309-1312, 1989.
27. Plate KH, Breier G, Weich HA, Risau W: Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature 35Y: 845-848, 1992.
28. Goldman CK, Kim J, Wong WL, King V, Brock T, Gillespie GY: Epidermal growth factor stimulates vascular endothelial growth factor production by human malignant glioma cells: a model of glioblastoma multiforme pathophysiology. Mol Biol Cell 4: 121-133, 1993.
29. Meir EG van, Polverini PJ, Chazin VR, Su Huang H-J, de Tribolet N, Cavenee WK: Release of an inhibitor of angiogenesis upon induction of wild-type p53 expression in glioblastoma cells. Nat Genet 8: 171-176, 1994.
30. Millauer B, Shawver LK, Plate KH, Risau W, Ullrich A: Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant. Nature 367: 576-579, 1994.
31. Czubayko F, Smith RV, Chung HC, Wellstein A: Tumor growth and angiogenesis induced by a secreted binding protein for fibroblast growth factors. J Biol Chem 269: 28243-28248, 1994.
32. Risau W: What, if anything, is an angiogenic factor? Cancer Metast Rev 15: 149-151, 1996.
33. Czubayko F, Liadet-Coopman EDE, Aigner A, Tuveson AT, Berchem GJ, Wellstein A: A secreted FGF-binding protein can serve as the angiogenic switch in human cancer. Nature Med 3: 1137-1140, 1997.
34. Rak J, Kerbel RS: bFGF and tumor angiogenesis -back in the limelight? Nature Med 3: 1083-1084, 1997.
35. Dameron KM, Volpert OV, Taisnky MA, Bouck N: Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science 265: 1582-1584, 1994.
36. Bertin N, Clezardin P, Kubiak R, Frappart L: Thrombospondin-1 and -2 messenger RNA expression in normal, benign, and neoplastic human breast tissues: correlation with prognostic factors, tumor angiogenesis, and fibroblastic desmoplasia. Cancer Res 57: 396-399, 1997.
37. Choudhuri R, Zhang H-T, Donnini S, Ziehe M, Bicknell R: An angiogenic role for the neurokines midkine and pleiotrophin in tumorigenesis. Cancer Res 57: 1814-1819, 1997.
38. Koochekpour S, Jeffers M, Rulong S, Taylor G, Klineberg E, Hudson EA, Resau JH, Vande Woude GF: Met and hepatocyte growth factor/scatter factor expression in human gliomas. Cancer Res 57: 5391-5398, 1997.
39. Bodey B, Bodey B Jr, Siegel SE, Kaiser HE: Upregulation of endoglin (CD105) expression during childhood brain tumor-related angiogenesis. Anti-angiogenic therapy. Anticancer Res (In print), 1998.
40. O'Brien T, Cranston D, Fuggle S, Bicknell R, Harris AL: Two mechanisms of basic fibroblast growth factor-induced angiogenesis in bladder cancer. Cancer Res 57: 136-140, 1997.
41. Holmgren L, O'Reilly MS, Folkman J: Dormancy of micrometastases: Balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nature Med 1: 149-153, 1995.
42. Samoto K, Ikezaki K, Ono M, Shono T, Kohno K, Kuwano M, Fukui M: Expression of vascular endothelial growth factor and its possible relation with neovascularization in human brain tumors. Cancer Res 55: 1189-1193, 1995.
43. Berkman RA, Merrill MJ, Reinhold WC, Monacci WT, Saxena A, Clark WC, Robertson JT, Ali IU, Oldfield EH: Expression of the vascular permeability factor /vascular endothelial growth factor gene in central nervous system neoplasms. J Clin Invest 91: 153-159, 1993.
44. Morii K, Tanaka R, Washiyama K, Kumanishi T, Kuwano R: Expression of vascular endothelial growth factor in capillary hemangioblastoma. Biochem Biophys Res Commun 194: 749-755, 1993.
45. Wizigmann-Voos S, Breier G, Risau W, Plate KH: Up-regulation of vascular endothelial growth factor and its receptors in von Hippel-Lindau disease-associated and sporadic hemangioblastomas. Cancer Res 55: 1358-1364, 1995.
46. Takano S, Yoshii Y, Kondo S, Suzuki H, Maruno T, Shirai S, Nose T: Concentration of vascular endothelial growth factor in the serum and tumor tissue of brain tumor patients. Cancer Res 56: 2185-2190, 1996.
47. Plate KH, Breier G, Weich HA, Mennel HD, Risau W: Vascular endothelial growth factor and glioma angiogenesis: coordinate induction of VEGF receptors, distribution of VEGF protein and possible in vivo regulatory mechanisms. Int J Cancer 59: 520-529, 1994.
48. Toi M, Yamamoto Y, Taniguchi T, Saji S, Hayashi K, Tominaga T: Regulation of endothelial growth factor expressions in breast cancer. Gan To Kagaku Ryoho 23(Suppl 1): 75-79, 1996.
49. Yoshiji H, Harris SR, Thorgeirsson UP: Vascular endothelial growth factor is essential for initial but not continued in vivo growth of human breast carcinoma cells. Cancer Res 57: 3924-3928, 1997.
50. Karaiossifidi H, Kouri E, Arvaniti H, Sfikas S, Vasilaros S: Tumor angiogenesis in node-negative breast cancer: relationship with relapse free survival. Anticancer Res 16: 4001-4002, 1996.
51. Gasparini G, Toi M, Gion M, Verderio P, Dittadi R, Hanatani M, Matsubara I, Vinante O, Bonoldi E, Boracchi P, Gatti C, Suzuki H, Tominaga T: Prognostic significance of vascular endothelial growth factor protein in node-negative breast carcinoma. J Natl Cancer Inst 89: 139-147, 1997.
52. Gitay-Goren H, Halaban R, Neufeld G: Human melanoma cells but not normal melanocytes express vascular endothelial growth factor receptors.Biochem Biophys Res Commun 190: 702-708, 1993.
53. Neufeld G, Tessler S, Gitay-Goren H, Cohen T, Levi BZ: Vascular endothelial growth factor and its receptors. Prog Growth Factor Res 5: 89-97, 1994.
54. Berger DP, Herbstritt L, Dengler WA, Marme D, Mertelsmann R, Fiebig HH: Vascular endothelial growth factor (VEGF) mRNA expression in human tumor models of different histologies. Ann Oncol 6: 817-825, 1995.
55. Liu B, Earl HM, Baban D, Shoaibi M, Fabra A, Kerr DJ, Seymour LW: Melanoma cell lines express VEGF receptor KDR and respond to exogenously added VEGF. Biochem Biophys Res Commun 217: 721-727, 1995.
56. Vinores SA, Kuchle M, Mahlow J, Chiu C, Green WR, Campochiaro PA: Blood-ocular barrier breakdown in eyes with ocular melanoma. A potential role for vascular endothelial growth factor/vascular permeability factor. Am J Pathol 147: 1289-1297; 1995.
57. Claffey KP, Brown LF, del Aguila LF, Tognazzi K, Yeo KT, Manseau EJ, Dvorak HF: Expression of vascular permeability factor/vascular endothelial growth factor by melanoma cells increases tumor growth, angiogenesis, and experimental metastasis. Cancer Res 56: 172-181, 1996.
58. Melnyk O, Shuman MA, Kim KJ: Vascular endothelial growth factor promotes tumor dissemination by a mechanism distinct from its effect on primary tumor growth. Cancer Res 56: 921 -924, 1996.
59. Marcoval J, Moreno A, Graells J, Vidai A, Escriba JM, Garcia-Ramirez M, Fabra A: Angiogenesis and malignant melanoma. Angiogenesis is related to the development of vertical (tumorigenic) growth phase. J Cutan Pathol 24: 212-218, 1997.
60. Salven P, Heikkila P, Joensuu H: Enhanced expression of vascular endothelial growth factor in metastatic melanoma. Br J Cancer 76: 930-934, 1997.
61. Barleon B, Totzke F, Herzog C, Blanke S, Kremmer E, Siemeister G, Marme D, Martiny-Baron G: Mapping of the sites for ligand binding and receptor dimerization at the extracellular domain of the vascular endothelial growth factor receptor FLT-1. J Biol Chem 272: 10382-10388, 1997.
62. Yuan F, Chen Y, Dellian M, Safabakhsh N, Ferrara a N, Jain RK: Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibody. Proc Natl Acad Sci U S A 93: 14765-14770, 1996.
63. Bouck N: Angiogenesis: a mechanism by which oncogenes and tumor suppressor genes regulate tumorigenesis. Cancer Treat Res 65: 359-371, 1992.
64. van den Hoff A: Stromal involvement in malignant growth. Adv Cancer Res 50: 159-196, 1988.
65. Risau W, Lemmon V: Changes in the vascular extracellular matrix during embryonic vasculogenesis and angiogenesis. Dev Biol 125: 441-450, 1988.
66. Neri D, Carnemolla B, Nissim A, Leprini A, Querze G, Balza E, Pini A, Tarli L, Halin C, Neri P, Zardi L, Winter G: Targeting by affinity-matured recombinant antibody fragments of an angiogenesis associated fibronectin isoform. Nature Biotechnol 15: 1271-1275, 1997.
67. Shweiki D, Itin A, Soffer D, Keshet E: Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 359: 843-845, 1992.
68. Kuroki M, Voest EE, Amano S, Beerepoot LV, Takashima S, Tolentino M, Kim RY, Rohan RM, Colby KA, Yeo KT, Adamis AP: Reactive oxygen intermediates increase vascular endothelial growth factor expression in vitro and in vivo. J Clin Invest 98: 1667-1675, 1996.
69. Lehnert SA, Akhurst RJ: Embryonic expression pattem of TGF-beta type I RNA suggests both paracrine and autocrine mechanisms of action. Development 104: 263-273, 1988.
70. Fox FE, Ford HC, Douglas R, Cherian S, Nowell PC: Evidence that TGF-beta can inhibit human T-lymphocyte proliferation through paracrine and autocrine mechanisms. Cellular Immunol 150: 45-58, 1993.
71. de Larco JE, Todaro GJ: Growth factors from murine sarcoma virus-transformed cells. Proc Natl Acad Sci USA 75: 4001-4005, 1978.
72. Todaro GJ, Fryling C, de Larco JE: Transforming growth factors produced by certain human tumor cells: polypeptides that interact with epidermal growth factor receptors. Proc Natl Acad Sci USA 77: 5258-5262, 1980.
73. Goustin AS, Leof EB, Shipley GD, Moses HL: Growth factors and cancer. Cancer Res 46: 1015-1029, 1986.
74. Massague J: Epidermal growth factor-like transforming growth factor. 1. Isolation, chemical characterization, and potentiation by other transfomming factors from feline sarcoma virus-transformed rat cells. J Biol Chem 258: 13606-13613, 1983.
75. Cheifetz S, Weatherbee JA, Tsang ML-S, Anderson JK, Mole JE, Lucas R, Massague J: The transfomling growth factor-beta system, a complex pattern of cross-reactive ligands and receptors. Cell 48: 409-415, 1987.
76. Van Obberghen-Schilling E, Roche NS, Flanders KC, Spom MB, Roberts AB: Transfomling growth factor beta 1 positively regulates its own expression in normal and transformed cells. J Biol Chem 263: 7741-7746, 1988.
77. Barnard JA, Beauchamp RD, Coffey RJ, Moses HL: Regulation of intestinal epithelial cell growth by transforming growth factor type beta. Proc Natl Acad Sci USA 86: 1578-1582, 1989.
78. Bascom CC, Wolfshohl JR, Coffey RJ, Madisen L, Webb NR, Purchio AR, Derynck R, Moses HL: Complex regulation of transforming growth factor betal, beta2, and beta3 mRNA expression in mouse fibroblasts and keratinocytes by transforming growth factors betal and beta2. Mol Cell Biol 9: 5508-5515, 1989.
79. Massague J, Andres J, Attisano L, Cheifetz S, Lopez-Casillas F, Ohtsuki M, Wrana JL: TGF-beta receptors. Mol Repr Dev 32: 99-104, 1992.
80. Massague J, Cheifetz S, Laiho M, Ralph DA, Weis FM, Zentella A: Transforming growth factor-beta. Cancer Surv 12: 81-103, 1992.
81. Barnard JA, Lyons RM, Moses HL: The cell biology of transforming growth factor beta. Biochim Biophys Acta 1032: 79-87, 1990
82. Attisano L, Wrana JL: Signal transduction by members of the transforming growth factor-beta superfamily. Cytokine Growth Factor Rev 7: 327-339, 1996.
83. ten Dijke P, Franzen P, Yamashita H, Ichijo H, Heldin CH, Miyazono K: Serine/threonine kinase receptors. Prog Growth Factor Res 5: 55-72, 1994.
84. Derynck R, Jarrett JA, Chen EY, Eaton DH, Bell JR, Assoian RK, Roberts AB, Sporn MB, Goeddel DV: Human transforming growth factor-beta complementary DNA sequence and expression in normal and transformed cells. Nature 316: 701-705, 1985.
85. Hanks SK, Annor R, Baldwin JH, Maldonado F, Spiess J, Holley RW: Amino acid sequence of the BSC-1 cell growth inhibitor (polyergin) deduced from the nucleotide sequence of the cDNA. Proc Natl Acad Sci USA 85: 79-82, 1988.
86. Madisen L, Webb NR, Rose TM, Marquardt H, Ikeda T, Twardzik D, Seyedin S, Purchio AF: Transforming growth factor-beta2: cDNA cloning and sequence analysis. DNA 7: 1-8, 1988.
87. ten Dijke P, Hansen P, Iwata KK, Peiler C, Foulkes JG: Identification of another member of the transforming growth factor type beta gene family. Proc Natl Acad Sci USA 85: 4715-4719, 1988.
88. Roberts AB, Sporn MB: The transforming growth factors beta. In: Handbook of experimental pharmacology, Vol 95/I: Peptide growth factors and their receptors. (Sporn MB, Roberts AB, eds) Springer Verlag, Heidelberg, 1990, pp 419-472.
89. Miyazono K: Transforming growth factor-beta and its receptors. Nippon Yakurigaku Zasshi 107: 133-140, 1996.
90. Miyazono K: TGF-beta receptors and signal transduction. Int J Hematol 65: 97-104, 1997.
91. Roberts AB, Frolik CA, Anzano MA, Sporn MB: Transforming growth factors from neoplastic and nonneoplastic tissues. Fed Proc 22: 2621-2626, 1983.
92. Frolik CA, Dart LL, Meyers CA, Smith DM, Sporn MB: Purification and initial characterization of a type beta transforming growth factor from human placenta. Proc Natl Acad Sci USA 80: 3676-3680, 1983.
93. Assoian RK, Komoriya A, Meyers CA, Miller DM, Sporn MB: Transforming growth factor-beta in human platelets: identification of a major storage site, purification, and characterization. J Biol Chem 258: 7155-7160, 1983.
94. Fujii D, Brissenden JE, Derynck R, Francke U: Transforming growth factor beta gene maps to human chromosome 19 long arm and to mouse chromosome 7. Somatic Cell Mol Genet 12: 281-288, 1986.
95. Barton DE, Foellmer BE, Du J, Tamm J, Derynck R, Francke U: Chromosomal mapping of genes for transforming growth factors beta 2 and beta 3 in man and mouse: dispersion of TGF-beta gene family. Oncogene Res 3: 323-331, 1988.
96. Wilcox JN, Derynck R: Developmental expression of Transforming Growth Factors alpha and beta in mouse fetus. Mol Cell Biology 8: 3415-3422, 1988.
97. Keller JR, Mcniece IK, Sill KT, Ellingsworth LR, Quesenberry PJ, Sing GK, Ruscetti FW: Transforming growth factor beta directly regulates primitive murine hematopoietic cell proliferation.Blood 75: 596-602, 1990.
98. Sharples K, Plowman GD, Rose TM, Twardzik DR, Purchio AF: Cloning and sequence analysis of simian transforming growth factor-beta cDNA. DNA 6: 239-244, 1987.
99. Derynck R, Rhee L: Sequence of the porcine transforming growth factor-beta precursor. Nucleic Acids Res 15: 3187, 1987.
100. Van Obberghen-Schilling E, Kondaiah P, Ludwig RL, Sporn MB, Baker CC: Complementary deoxyribonucleic acid cloning of bovine transforming growth factor-beta 1. Mol Endocrinol 1: 693-698, 1987.
101. Fontana A, Hengartner H, de Tribolet N, Weber E: Glioblastoma cells release interleukin 1 and factors inhibiting interleukin 2-mediated effects. J Immunol 132: 1837-1844, 1984.
102. Wrann M, Bodmer S, de Martin R, Siepl C, Hofer-Warbinek R, Fei K, Hofer E, Fontana A: T cell suppressor factor from human glioblastoma cells is a 12.5-kd protein closely related to transforming growth factor beta. EMBO J 6: 1633-1636, 1987.
103. Siepl C, Bodmer S, Frei K, MacDonald HR, De Martin R, Hofer E, Fontana A: The glioblastoma-derived T cell suppressor factor/transforming growth factor-beta 2 inhibits T cell growth without affecting the interaction of interleukin 2 with its receptor. Eur J Immunol 18: 593-600, 1988.
104. Frolik CA, Wakefield LM, Smith DM, Sporn MB: Characterization of a membrane receptor for transforming growth factor-beta in normal rat kidney fibroblasts. J Biol Chem 259: 10995-11000, 1984.
105. 125I-labeled type beta transforming growth factor from human platelets. Proc Natl Acad Sci USA 81: 6757-6761, 1984.
106. Massague J: Type beta transforming growth factor from feline sarcoma virus-transformed cells. Isolation and biological properties. J Biol Chem 259: 9756-9761, 1984.
107. Segarini PR: TGF-beta receptors. Clinical applications of TGF-beta. Wiley, Chichester (CIBA Foundation Symposium # 157), 1991; pp 29-50.
108. Massague J, Like B: Cellular receptors for type beta transforming growth factor. Ligand binding and affinity labeling in human and rodent cell lines. J Biol Chem 260: 2636-2645, 1985.
109. Wrana JL, Carcamo J, Attisano L, Cheifetz S, Zentella A, Lopez-Casillas F, Massague J: The type II TGF-beta receptor signals diverse responses in cooperation with the type I receptor. Cold Spring Harb Symp Quant Biol 57: 81-86, 1992.
110. Laiho M, Weis FMB, Boyd FT, Ignotz RA, Massague J: Responsiveness of transforming growth factor beta (TGF-beta) restored by genetic complementation between cells defective in TGF-beta receptors I and II. J Biol Chem 266: 9108-9112, 1992.
111. Lin HY, Wang X-F, Ng-Eaton E, Weinberg RA, Lodish HF: Expression cloning of the TGF-beta type II receptor, a functional transmembrane serine/threonine kinase. Cell 68: 775-785, 1992.
112. Bodey B, Bodey B Jr, Hall FL: Expression of Transforming Growth Factor-beta type II receptors in the cells of the human thymic microenvironment during ontogenesis. In: Molecular Biology of Hematopoiesis. Volume V. (Abraham NG, Asano S, Brittinger G, Maestroni GJM, Shadduck R, eds) New York, Plenum Press, 1996, Chapter 78, pp. 645-658.
113. Burrows FJ, Derbyshire EJ, Tazzari PL, Amlot P, Gazdzar AF, King SW, Letarte M, Vitetta ES, Thorpe PE: Up-regulation of endoglin on vascular endothelial cells in human solid tumors: Implications for diagnosis and therapy. Clin Cancer Res 1: 1623-1634, 1995.
114. Kumar P, Wang JM, Bernabeu C: CD 105 and angiogenesis. J Pathol 178: 363-366, 1996.
115. Fernandez-Ruiz E, St-Jacques S, Bellon T, Letarte M, Bernabeu C: Assignment of the human endoglin gene (END) to 9q34->qter. Cytogenet Cell Genet 64: 204-207, 1993.
116. Wang JM, Kumar S, van Agthoven A, Kumar P, Pye D, Hunter RD: Irradiation induces up-regulation of E9 protein (CD105) in human vascular endothelial cells. Int J Cancer 62: 791 -796, 1995.
117. Yamada N, Kato M, Yamashita H, Nister M, Miyazono K, Heldin CH, Funa K: Enhanced expression of transforming growth factor-beta and its type-I and type-II receptors in human glioblastoma. Int J Cancer 62: 386-392, 1995.
118. Henriksen R, Gobi A, Wilander E, Oberg K, Miyazono K, Funa K: Expression and prognostic significance of TGF-beta isotypes, latent TGF-beta I binding protein, TGF-beta type I and type II receptors, and endoglin in normal ovary and ovarian neoplasms. Lab Invest 73: 213-220, 1995.
119. Szekanecz Z, Haines GK, Harlow LA, Shah MR, Fong TW, Fu R, Lin SJ, Rayan G, Koch AE: Increased synovial expression of transforming growth factor (TGF)-beta receptor endoglin and TGF-beta 1 in rheumatoid arthritis: possible interactions in the pathogenesis of the disease. Clin Immunol Immunopathol 76: 187-194, 1995.
120. Zhang H, Shaw AR, Mak A, Letarte M: Endoglin is a component of the transforming growth factor (TGF)-beta receptor complex of human pre-B leukemic cells. J Immunol 156: 564-573, 1996.
121. Griffioen AW, Damen CA, Blijham GH, Groenewegen G: Endoglin/CD 105 may not be an optimal tumor endothelial treatment target. Breast Cancer Res Treat 39: 239-242, 1996.
122. Shovlin CL, Scott J: Inherited diseases of the vasculature. Annu Rev Physiol 58: 483-507, 1996.
123. Pichuantes S, Vera S, Bourdeau A, Pece N, Kumar S, Wayner EA, Letarte M: Mapping epitopes to distinct regions of the extracellular domain of endoglin using bacterially expressed recombinant fragments. Tissue Antigens 50: 265-276, 1997.
124. Gougos A, Letarte M: Primary structure of endoglin, an RGD-containing glycoprotein of human endothelial cells. J Biol Chem 265: 8361-8364, 1990.
125. Lopez-Casillas F, Cheifetz S, Doody J, Andres JL, Lane WS, Massague J: Structure and expression of the membrane proteoglycan betaglycan, a component of the TGF-beta receptor system.Cell 67: 785-795, 1991.
126. Altomonte M, Montagner R, Fonsatti E, Colizzi F, Cattarossi I, Brasoveanu LI, Nicotra MR, Cattelan A, Natali PG, Maio M: Expression and structural features of endoglin (CD105), a transforming growth factor beta 1 and beta 3 binding protein, in human melanoma.Br J Cancer 74: 1586-1591, 1996.
127. Cheifetz S, Bellon T, Cales C, Vera S, Bemabeu C, Massague J, Letarte M: Endoglin is a component of the transforming growth factor-beta receptor system in human endothelial cells. J Biol Chem 267: 19027-19030, 1992.
128. Lastres P, Bellon T, Cabanas C, Sanchez-Madrid F, Acevedo A, Gougos A, Letarte M, Bemabeu C: Regulated expression on human macrophages of endoglin, an Arg-Gly-Asp-containing surface antigen. Eur J Immunol 22: 393-397, 1992.
129. Westphal JR, Willems HW, Schalkwijk CJ, Ruiter DJ, de Waal RM: A new 180-kDa dermal endothelial cell activation antigen: in vitro and in situ characteristics. J Invest Dermatol 100: 27-34, 1993.
130. Westphal JR, Willems HW, Schalkwijk CJ, Ruiter DJ, De Waal RM: Characteristics and possible function of endoglin, a TGF-beta binding protein. Behring Inst Mitt 92: 15-22, 1993.
131. Lopez-Casillas F, Payne HM, Andres JL, Massague J: Betaglycan can act as a dual modulator of TGF-beta access to signaling receptors: mapping of ligand binding and GAG attachment sites. J Cell Biol 124: 557-568, 1994.
132. Cheifetz S, Bellon T, Cales C, Vera S, Bemabeu C, Massague J, Letarte M: Endoglin is a component of the transforming growth factor-beta receptor system in human endothelial cells. J Biol Chem 267: 19027-19030, 1992.
133. Yamashita H, Ichijo H, Grimsby S, Moren A, ten Dijke P, Miyazono K: Endoglin forms a heteromeric complex with the signaling receptors for transforming growth factor-beta. J Biol Chem 269: 1995-2001, 1994.
134. Lastres P, Martin-Perez J, Langa C, Bemabeu C: Phosphorylation of the human-transforming-growth-factor-beta-binding protein endoglin. Biochem J 301: 765-768, 1994.
135. Bellon T, Corbi A, Lastres P, Cales C, Cebrian M, Vera S, Cheifetz S, Massague J, Letarte M, Bernabeu C: Identification and expression of two forms of the human transforming growth factor-beta-binding protein endoglin with distinct cytoplasmic regions. Eur J Immunol 23: 2340-2345, 1993.
136. Lastres P, Letamendia A, Zhang H, Rius C, Almendro N, Raab U, Lopez LA, Langa C, Fabra A, Letarte M, Bernabeu C: Endoglin modulates cellular responses to TGF-ß 1. J Cell Biol 133: 1109-1121, 1996.
137. Farmilo AJ, Stead RH: Fixation in immunocytochemistry. In: Handbook Immunochemical Staining Methods. (Naish SJ, ed) DAKO Corporation, 1989, pp24-29.
138. Weidner N: Intratumoral microvessel density as a prognostic factor in cancer. Am J Pathol 147: 9-19, 1995.
139. Martin L, Holcombe C, Green B, Leinster SJ, Winstanley J: Is a histological section representative of whole tumour vascularity in breast cancer? Brit J Cancer 76: 40-43, 1997.
140. Bodey B, Gröger AM, Bodey B Jr, Siegel SE, Kaiser HE: Immunocytochemical detection of p53 protein expression in various childhood astrocytoma subtypes: Significance in tumor progression. Anticancer Res 17: 1187-1194, 1997.
141. Bodey B, Bodey B Jr, Siegel SE, Luck JV, Kaiser HE: Immunophenotypic characterization of human primary and metastatic melanoma infiltrating autologous immunological effector cells. Anticancer Res 16: 3439-3446, 1996.
142. Bodey B, Bodey B Jr, Gröger AM, Siegel SE, Kaiser HE: Clinical and prognostic significance of Ki-67 and proliferating cell nuclear antigen expression in childhood primitive neuroectodermal brain tumors. Anticancer Res 17: 189-196, 1997.
143. Bodey B, Bodey B Jr, Gröger AM, Siegel SE, Kaiser HE: Nm23/nucleoside diphosphate (NDP) kinase expression in human malignant melanomas. Significance and implications in tumor biology. Anticancer Res 17: 505-512, 1997.
144. Bodey B, Gröger AM, Bodey B Jr, Siegel SE, Kaiser HE: Immunocytochemical detection of p53 protein overexpression in primary human osteosarcomas. Anticancer Res 17: 493-498, 1997.
145. Bodey B, Bodey B Jr, Gröger AM, Luck JV, Siegel SE, Taylor CR, Kaiser HE: Immunocytochemical detection of the p 170 multidrug resistance (MDR) and the p53 tumor suppressor gene proteins in human breast cancer cells: Clinical and therapeutical significance. Anticancer Res 17: 1311-1318, 1997.
146. Bodey B, Bodey B Jr, Gröger AM, Luck JV, Siegel SE, Taylor CR, Kaiser HE: Clinical and prognostic significance of the expression of the c-erbB-2 and c-erbB-3 oncoproteins in primary and metastatic malignant melanomas and breast carcinomas. Anticancer Res 17: 1319-1330, 1997.
147. Bodey B, Zeltzer PM, Saldivar V, Kemshead J: Immunophenotyping of childhood astrocytomas with a library of monoclonal antibodies. Int J Cancer 45: 1079-1087, 1990.
148. Battifora H: The multitumor (sausage) tissue block: novel method for immunohistochemical antibody testing. Lab Invest 55: 244-248, 1986.
149. Battifora H, Mehta P: The checkerboard tissue block. An improved multitissue control block. Lab Invest 63: 722-724, 1990.
150. Clark WC, Bressler J: Transforming growth factor-ß-like activity in tumors of the central nervous system. J Neurosurg 68: 920-924, 1988.
151. Zagzag D, Brem S, Robert F: Neovascularization and tumor growth in the rabbit brain: a model for experimental studies of angiogenesis and the blood-brain barrier. Am J Pathol 131: 361-372, 1988.
152. Zagzag D, Miller DC, Sato Y, Rifkin DB, Burstein DE: Immunohistochemical localization of basic fibroblast growth factor in astrocytomas. Cancer Res: 50: 7393-7398, 1990.
153. Mapstone TB: Expression of platelet-derived growth factor and transforming growth factor and their correlation with cellular morphology in glial tumors. J Neurosurg 75: 447-451, 1991.
154. Brem S, Tsanaclis AMC, Gately S, Gross JL, Herblin WF: Immunolocalization of basic fibroblast growth factor to the microvasculature of human brain tumors. Cancer 70: 2673-2680, 1992.
155. Takashashi JA, Fukumoto M, Igarashi K, Oda Y, Kikuchi H, Hatanaka M: Correlation of basic fibroblast growth factor expression levels with the degree of malignancy and vascularity in human gliomas. J Neurosurg 76: 792-798, 1992.
156. Kim KJ, Li B, Winer J, Armanini M, Gillett N, Phillips HS, Ferrara N: Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumor growth in vivo. Nature 362: 841-844, 1993.
157. Vitolo D, Paradiso P, Uccini S, Ruco LP, Baroni CD: Expression of adhesion molecules and extracellular matrix proteins in glioblastomas: relation to angiogenesis and spread. Histopathology 28: 521-528, 1996.
158. Krasagakis K, Garbe C, Schrier PI, Orfanos CE: Paracrine and autocrine regulation of human melanocyte and melanoma cell growth by transforming growth factor beta in vitro. Anticancer Res 14: 2565-2571, 1994.
159. Andalib AR, Lawry J, Ali SA, Murray AK, Sisley K, Silcocks P, Herlyn M, Rees RC: Cytokine modulation of antigen expression in human melanoma cell lines derived from primary and metastatic tumour tissues. Melanoma Res 7: 32-42, 1997.
160. Ma D, Niederkorn JY: Transforming growth factor-beta down-regulates major histocompatibility complex class I antigen expression and increases the susceptibility of uveal melanoma cells to natural killer cell-mediated cytoiysis. Immunology 86: 263-269, 1995.
161. Vanky F, Nagy N, Hising C, Sjovall K, Larson B, Klein E: Human ex vivo carcinoma cells produce transforming growth factor beta and thereby can inhibit lymphocyte functions in vitro. Cancer Immunol Immunother 43-317-323, 1997.
162. Moretti S, Pinzi C, Berti E, Spallanzani A, Chiarugi A, Boddi V, Reali UM, Giannotti B: in situ expression of transforming growth factor beta is associated with melanoma progression and correlates with Ki67, HLA-DR and beta 3 integrin expression. Melanoma Res 7: 313-321, 1997.
163. Teti A, De Giorgi A, Spinella MT, Migliaccio S, Canipari R, Onetti Muda A, Faraggiana T: Transforming growth factor-beta enhances adhesion of melanoma cells to the endothelium in vitro. Int J Cancer 72: 1013-1020, 1997,
164. Van Belle P, Rodeck U, Nuamah I, Halpern AC, Elder DE: Melanoma-associated expression of transforming growth factor-beta isoforms. Am J Pathol 148: 1887-1894, 1996.
165. Reed JA, McNutt NS, Prieto VG, Albino AP: Expression of transforming growth factor-beta 2 in malignant melanoma correlates with the depth of tumor invasion. Implications for tumor progression. Am J Pathol 145: 97-104, 1994.
166. Altomonte M, Montagner R, Fonsatti E, Colizzi F, Cattarossi I, Brasoveanu LI, Nicotra MR, Cattelan A, Natali PG, Maio M: Expression and structural features of endoglin (CD105), a transforming growth factor betal and beta3 binding protein, in human melanoma. Br J Cancer 74: 1586-1591, 1996.
167. Greene HSN: The transplantation of human brain tumors to the brain of laboratory animals. Cancer Res 13: 422-426, 1953.
168. Bennett HS, Luft JH, Hampton JL: Morphological classification of vertebrate blood capillaries. Amer J Physiol 196: 381-390, 1959.
169. Dobbing J: The blood-brain barrier. Physiol Rev 41: 130-188, 1961.
170. Donahue S, Pappas G: Fine structure of capillaries of cerebral cortex of rat at stages of development. Amer J Anat 108: 331-349, 1961.
171. Tschirgi R: Blood-brain barrier: Fact or fantasy? Fed Proc 21: 665-676, 1962.
172. Shimoda A: An electron microscopic study of the developing rat brain concerned with the morphological basis of the blood-brain barrier. Acta Path Jap 13: 95-105, 1963.
173. Fox JL: Developments of recent thoughts on intracranial pressure and the blood-brain barrier. J Neurosurg 21: 909-967, 1964.
174. Krigman MR, Manuelidis EE: Morphological and permeability changes in the cerebral parenchyma adjacent to heterologous intracerebral tumors. J Neuropath Exp Neurol 22: 368-373, 1965.
175. Manuelidis EE, Dolin R: Fine structural studies on the vascularization of heterologously transplanted tumors. Ann NY Acad Sci 159: 432-445, 1969.
176. Roberts WG, Palade GE: Neovasculature induced by vascular endothelial growth factor is fenestrated. Cancer Res 57: 765-772, 1997.
177. Rettig WJ, Garin-Chesa P, Healey JH, Su SL, Jaffe EA, Old LJ: Identification of endosialin, a cell surface glycoprotein of vascular endothelial cells in human cancer. Proc Natl Acad Sci USA 89: 10832-10836, 1992.
178. Folkman J: Tumor angiogenesis: Therapeutic implications. N Engl J Med 285: 1182-1186, 1971.
179. Folkman J: Clinical applications of research on angiogenesis. N Engl J Med 333: 1757-1763, 1995.
180. Fidler IJ, Ellis LM: The implications of angiogenesis for the biology and therapy of cancer metastasis. Cell 79: 185-188, 1994.
181. Gasparini G, Harris AL: Clinical importance of the determination of tumor angiogenesis in breast carcinoma: Much more than a new prognostic tool. J Clin Oncol 13: 765-782, 1995.
182. Folkman J: Fighting cancer by attacking its blood supply. Sci Am 275: 150-154, 1996.
183. Folkman J: New perspectives in clinical oncology from angiogenesis research. Eur J Cancer 32A: 2534-2534, 1996.
184. Dark GG, Hill SA, Prise VE, Tozer GM, Pettit GR, Chaplin DJ: Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature. Cancer Res 57: 1829-1834, 1997.
185. D'Amato RJ, Loughman MS, Flynn E, Folkman J: Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 91: 4082-4085, 1994.
186. Takano S, Gately S, Neville ME, Herblin WF, Gross JL, Engelhard H, Perricone M, Eidsvoog K, Brem S: Suramin, an anticancer and angiosuppressive agent, inhibits endothelial cell binding of basic fibroblast growth factor, proliferation, and induction of urokinasetype plasminogen activator. Cancer Res 54: 2654-2660, 1994.
187. Takamiya Y, Brem H, Ojeifo J, Mineta T, Martuza RL: AGM-1470 inhibits the growth of human glioblastoma cells in vitro and in vivo. Neurosurgery 34: 869-875, 1994.
188. Bosse DC, Parker JT, Vogler WR, Ades EW: Selective inhibition of adhesion molecule expression by edelfosine (ET-18-OCH3) on human umbilical vein or microvascular endothelium. Pathobiology 63: 109-114, 1995.
189. Voest EE, Kenyon BM, O'Reilly MS, Truitt G, D'Amato RJ, Folkman J: Inhibition of angiogenesis in vivo by interleukin-12. J Natl Cancer Inst 87: 581-586, 1995.
190. Konno H, Tanaka T, Kanai T, Maruyama K, Nakamura S, Baba S: Efficacy of an angiogenesis inhibitor, TNP-470, in xenotransplanted human colorectal cancer with high metastatic potential. Cancer 77: 1736-1740, 1996.
191. Maier JA, Delia D, Thorpe PE, Gasparini G: In vitro inhibition of endothelial cell growth by the antiangiogenic drug AGM-1470 (TNP-470) and the anti-endoglin antibody TEC-11. Anticancer Drugs 8: 238-244, 1997.
192. Lannutti BJ, Gately ST, Quevedo ME, Soff GA, Paller AS: Human angiostatin inhibits murine hemangioendothelioma tumor growth in vivo. Cancer Res 57: 5277-5280, 1997.
193. O'Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, Flynn E, Birkhead JR, Olsen BR, Folkman J: Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 88: 277-285, 1997.
194. Klauber N, Parangi S, Flynn E, Hamel, E, D'Amato RJ: Inhibition of angiogenesis and breast cancer in mice by the microtubule inhibitors 2-methoxyestradiol and taxol. Cancer Res 57: 81-86, 1997.
195. Sim BKL, O'Reilly MS, Liang H, Fortier AH, He W, Madsen JW, Lapcevich R, Nacy CA: A recombinant human angiostatin protein inhibits experimental primary and metastatic cancer. Cancer Res 57: 1329-1334, 1997.
196. Boehm T, Folkman J, Browder TT, O'Reilly MS: Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 390: 404-407, 1997.
197. Lindner DJ, Borden EC: Effects of tamoxifen and interferon-beta or the combination on tumor-induced angiogenesis. Int J Cancer 71: 456-461, 1997.
198. Meir EG van, Polverini PI, Chazin VR, Su Huang HJ, Tribolet N de, Cavenee WK: Release of an inhibitor of angiogenesis upon induction of wild-type p53 expression in glioblastoma cells. Nature Genet 8: 171-176, 1994.
199. Rak J, Mitsuhashi Y, Bayko L, Filmus J, Shirasawa S, Sasazuki T, Kerbel RS: Mutant ras oncogenes upregulate VEGF/VPF expression: implications for induction and inhibition of tumor angiogenesis. Cancer Res 55: 4575-4580, 1995.
200. Rak J, Filmus J, Finkenzeller G, Grugel S, Marme D, Kerbel RS: Oncogenes as inducers of tumor angiogenesis. Cancer Metastasis Rev 14: 263-277, 1995.
201. Plate KH: Gene therapy of malignant glioma via inhibition of tumor angiogenesis. Cancer Metast Rev 15: 237-240, 1996.
202. Wojtowicz-Praga S, Verma UN, Wakefield L, Esteban JM, Hartmann D, Mazumder A: Modulation of B 16 melanoma growth and metastasis by anti-transforming growth factor beta antibody and interleukin-2. J Immunother Emphasis Tumor Immunol 19: 169-175, 1996.